Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.

pramipexole

Adjunctive therapy

Brand: Mirapex

Published 2025-12-23 · Last reviewed 2025-12-30 · 4 references

Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.

Print sheet Review evidence

At a glance

Class: Adjunctive therapy·Typical dose: RLS: start 0.125 mg once daily 2 to 3 hours before bedtime; dose may be increased every 4 to 7 days based on response and tolerability (label).·Half-life: Single-dose range 8–12 h·LAI available: No

Class: Adjunctive therapy
Typical dose: RLS: start 0.125 mg once daily 2 to 3 hours before bedtime; dose may be increased every 4 to 7 days based on response and tolerability (label).
Half-life: Single-dose range 8–12 h
LAI available: No

Quick answers

What is pramipexole?: Pramipexole (brand Mirapex) is a non-ergoline dopamine agonist indicated for Parkinson’s disease and moderate-to-severe primary RLS (label).
What is Mirapex?: Mirapex is a brand name for pramipexole.
What is Mirapex (pramipexole) used for?: Label indications include: Parkinson’s disease (PD) and moderate-to-severe primary restless legs syndrome (RLS) (label).
What drug class is Mirapex (pramipexole)?: Dopamine Agonist.
What is the mechanism of action of Mirapex (pramipexole)?: Non-ergoline dopamine agonist (D2/D3-preferring) indicated for Parkinson’s disease and moderate-to-severe primary restless legs syndrome; largely renally eliminated as unchanged drug with clinically important somnolence, impulse- control, hallucination/psychosis, and RLS augmentation considerations.
What strengths does Mirapex (pramipexole) come in?: Tablets: 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, and 1.5 mg (label).

General information

Pramipexole (brand Mirapex) is a non-ergoline dopamine agonist indicated for Parkinson’s disease and moderate-to-severe primary RLS (label).

In RLS, dopamine agonists can improve symptoms but require long-term risk management. A key concern is augmentation, which shapes follow-up plans and influences drug selection frameworks (guideline/clinical).

Clinically important adverse effects include somnolence/sudden sleep onset, orthostatic hypotension, hallucinations/psychosis, and impulse-control symptoms; these risks can be especially relevant in serious mental illness (label/clinical).

Pramipexole is largely renally eliminated as unchanged drug; dosing and tolerability are tied to kidney function and require adjustment in renal impairment (label).

The pramipexole compare view, evidence feed, and print page support side-by-side review of RLS options and monitoring topics.

U.S. approvals

Parkinson’s disease (PD)
Moderate-to-severe primary restless legs syndrome (RLS)

Formulations & strengths

Tablets: 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, and 1.5 mg (label).

Generic availability

Widely available generically.

In RLS, pramipexole is usually positioned with explicit monitoring for augmentation and neuropsychiatric adverse effects. In patients with mood or psychotic disorders, dopaminergic activation risks can be clinically limiting and may shift preference toward non-dopaminergic strategies (guideline/clinical).

View labelExact

Mechanism of action

Refer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.

Dopamine agonist with high relative affinity for D2/D3 receptor subtypes (label/class).

Clinical effects in PD reflect dopaminergic stimulation; in RLS, dopaminergic system involvement is a common mechanistic frame (label/class).

Dopaminergic therapies can precipitate or worsen hallucinations, impulsivity, and mood destabilization in vulnerable patients, which is relevant in serious mental illness (label/clinical).

Dopamine receptor agonism (D2/D3 preference; class-level).

Metabolism & pharmacokinetics

Pramipexole is rapidly absorbed with high oral bioavailability and is metabolized only to a negligible extent (<10%) (label).
Urinary excretion is the major route of elimination; ~90% of a dose is recovered in urine, almost all as unchanged drug (label).
Terminal half-life is ~8 hours in younger adults and ~12 hours in older adults; steady state is typically achieved within ~2 days (label).

Dosing & administration

RLS: start 0.125 mg once daily 2 to 3 hours before bedtime; dose may be increased every 4 to 7 days based on response and tolerability (label).
For RLS, there is no evidence that 0.75 mg provides additional benefit beyond 0.5 mg (label).
Renal impairment requires dose adjustment; dose selection is based on creatinine clearance (label).
Parkinson’s disease uses different titration schedules and higher total daily doses than RLS; indication-specific dosing is important (label).

Monitoring & labs

Somnolence and sudden sleep onset monitoring; driving safety review (label).
Orthostatic blood pressure and dizziness/falls risk monitoring (label/clinical).
Hallucinations/psychosis and mood destabilization monitoring, especially in serious mental illness (label/clinical).
Impulse-control symptom monitoring (new compulsive behaviors) (label/clinical).
RLS symptom timing tracking to detect augmentation (earlier onset, increased severity, spread) (guideline/clinical).
Renal function review and renal-dose adjustment as needed (label).

Adverse effects

FDA boxed warnings

Common side effects (≥10%)

Nausea: Common and dose-related; titration speed affects tolerability (label/clinical).
Somnolence / sudden sleep onset: Can be safety-critical; assess next-day impairment and driving risk (label).
Dizziness / orthostatic hypotension: More common during titration and in older adults; monitor falls risk (label/clinical).

Other notable effects

Hallucinations, confusion, and psychotic symptoms can occur and may be more likely in older adults or those with baseline psychiatric vulnerability (label/clinical).
Impulse-control symptoms (e.g., compulsive behaviors) have been reported with dopamine agonists; monitoring for behavioral change is clinically important (label/clinical).
In RLS, long-term use can be complicated by augmentation and rebound, which may present as earlier onset or worsening severity (guideline/clinical).

Interactions

Pramipexole has negligible CYP metabolism; CYP-based interactions are limited (label).
Cimetidine and other inhibitors of renal tubular secretion can increase exposure and half-life; monitoring for increased adverse effects is commonly considered when these are started or stopped (label).
Additive sedation can occur with alcohol and other CNS depressants (label/clinical).

Other useful information

RLS care frameworks emphasize screening for contributors (iron deficiency, sleep apnea, medication triggers) and reassessing treatment when symptoms shift earlier in the day or intensify (guideline/clinical).
AASM guidance and updated algorithms highlight augmentation monitoring and support use of non-dopaminergic options when augmentation risk or psychiatric vulnerability is high (guideline).

References

Related hubs:SMI toolkit·Support resources